ClinicalTrials.gg
TerminatedNCT05653583Updated Oct 21, 2026

Peripheral Nerve Stimulation Therapy for Atrial Fibrillation

An interventional study of Wrist Device and Ear Device in Atrial Fibrillation, sponsored by Cala Health, Inc.. Terminated at 2 sites in United States. Open to participants aged 22 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Cala Health, Inc. · Not applicable, Interventional, and Other

How we know

Why this study was terminated
The Sponsor and Principal Investigator have mutually agreed to initiate study closure due to prolonged recruitment challenges that have prevented the trial from meeting its enrollment milestones within the projected study timeline.

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 1 month ago, and no results have been posted to the registry.
Updated Oct 21, 2026Now TerminatedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
22 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 993 studies in Atrial Fibrillation with a site in United States — 160 open to participants now, 220 under way, 15 of them phase 3. Atrial Fibrillation · United States.

Enrollment
587th of 679
15 · median 127
Started
2023
with 54 others
No phase
405 of 993
67 open now
Registered
811th of 993
by date

Among the 993 studies in Atrial Fibrillation with a site in United States, this one is the 587th largest by enrollment of the 679 interventional ones that give a count, is one of 55 that started in 2023, is one of 405 with no phase, and was the 811th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

160 of the 993 studies in Atrial Fibrillation with a site in United States are open now. Recruiting first, the newest first:

155 more — sign in →

All 160 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 22 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 993 studies in Atrial Fibrillation with a site in United States, or all of them as a file.
02

Study summary

This is a three-arm, single-blinded, randomized, sham-controlled, nonsignificant risk study to assess the feasibility of reducing Atrial Fibrillation burden with peripheral nerve stimulation. The three arms include treatment with a wrist-worn neuromodulation ("wrist device"), treatment with an ear-worn neuromodulation device ("ear device") and sham stimulation with wrist-worn device that does not actually deliver stimulation ("sham device"). ECG patches will be worn on the chest to measure AF episode onset and duration ("ECG Patch"). Finally, subjects will track AF episode onset, duration, and symptom type in an AF diary.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 21, 2026. See what changed

Ages eligible
22 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 22 years of age and up to 85 years of age
  • Diagnosed with paroxysmal atrial fibrillation, as documented on , trans-telephonic monitoring (TTM), cardiac event monitoring, Holter monitoring, or implantable loop recording (episodes must be longer than 30 seconds to qualify)
  • At least two symptomatic or asymptomatic atrial fibrillation episodes over the last month, or at least one symptomatic or asymptomatic atrial fibrillation episode in the last two weeks
  • On anticoagulants if indicated by treatment guidelines
  • Willing to stay on stable medications for the duration of the study
  • Competent and willing to provide written, to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Cardiac ablation within the last 6 months, or cardiac ablation planned within 8 weeks of Visit 1
  • Cardioversion procedure performed within the last 12 weeks
  • Valvular atrial fibrillation by transthoracic echocardiography
  • Abnormal left atrial enlargement, as measured by left atrial anteroposterior diameter greater than 5.5 cm or left atrial volume index greater than 48 mL/m2
  • Prior or planned cardiac transplantation or cardiac surgery
  • Cerebral ischemic event (stroke or ) within the last 6 months
  • Myocardial infarction within the last 6 months
  • Heart failure ( class III or IV)
  • less than 35%
  • Recurrent vaso-vagal syncopal episodes
  • Unilateral or bilateral vagotomy
  • Hemodynamic instability
  • Structural heart damage
  • Implanted active electrical medical device, such as pacemaker, implantable loop recorders, defibrillator, or deep brain stimulator
  • Implanted metal or electrical devices in the head or treated hand
  • History of epilepsy or seizures
  • Peripheral neuropathy affecting the upper left extremity
  • Pregnancy, anticipated pregnancy, or nursing during the study
  • Unable or unwilling to comply fully with study procedures and followup, including atrial fibrillation diary requirements
  • Known allergy to any of the device materials that are in contact with prospective subject's skin
  • Current participation, or previous participation within the last 30 days, in another interventional clinical trial that may confound the results of this study, unless otherwise approved by the Sponsor
  • Subjects unable to communicate with the Investigator and study staff
  • Presence of any health condition that should preclude participation in this study, per the Investigator's opinion
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
15 participants (actual)

Study arms

  • Active comparator
    Wrist Device

    Twice daily stimulation sessions during the 4-week treatment period

    Device: Wrist Device

  • Active comparator
    Ear Device

    Twice daily stimulation sessions during the 4-week treatment period

    Device: Ear Device

  • Sham comparator
    Sham Device

    Twice daily "stimulation" sessions during the 4-week treatment period

    Device: Sham Device

Interventions

  • DeviceWrist Device

    peripheral nerve stimulation via wrist-worn device

  • DeviceEar Device

    peripheral nerve stimulation via ear-worn device

  • DeviceSham Device

    Wrist-worn device that does not actually deliver stimulation

06

What researchers measure

Primary outcomes

  1. Percentage of time spent in AF during the treatment period compared to the run-in period (prior to treatment) for AF episodes >= 30 seconds duration

    Time frame: 8 weeks

Secondary outcomes

  1. Time to first recurrence of any AF (>= 30 seconds duration) during treatment period compared to run-in period

    Time frame: 8 weeks

  2. Time to first recurrence of symptomatic AF during treatment period compared to run-in period

    Time frame: 8 weeks

  3. Average AF episode duration during the treatment period compared to the run-in period (for episodes >= 30seconds duration)

    Time frame: 8 weeks

  4. Number of AF episodes lasting >= 5.5 hours

    Time frame: 8 weeks

  5. Average duration of ongoing AF episodes (>= 30 seconds duration) following the start of therapy sessions

    Time frame: 8 weeks

  6. Atrial Fibrillation Effect on Quality of Life (AFEQL) score at the end of the treatment period compared to end of the run-in period

    Time frame: 8 weeks

  7. Compliance to per-protocol therapy measured by the percentage of full and partial therapy sessions delivered relative to total sessions required per-protocol

    Time frame: 8 weeks

  8. Compliance of daily therapy measured by the percentage of treatment days subjects performed full or partial therapy sessions

    Time frame: 8 weeks

Other outcomes

  1. Number of AF-related emergency visits

    Time frame: 8 weeks

  2. Number of AF-related in-patient hospitalizations

    Time frame: 8 weeks

  3. Number of cardioversion procedures

    Time frame: 8 weeks

07

Study locations

2 sites
  • Mayo Clinic
    Rochester, Minnesota 55902, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2023 to primary completion in Sep 2025, 30 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Dec 2023 → Sep 2025 and completion Dec 2023 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2022
First posted
Dec 16, 2022
StartActual
Mar 8, 2023
Primary completionActual
Sep 24, 2025was Dec 2023
CompletionActual
Sep 15, 2026was Dec 2023
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Terminated The Sponsor and Principal Investigator have mutually agreed to initiate study closure due to prolonged recruitment challenges that have prevented the trial from meeting its enrollment milestones within the projected study timeline.
changed Oct 21, 2026
Primary completion
Dec 2023→Sep 24, 2025 (actual)
Oct 21, 2026
Study completion
Dec 2023→Sep 15, 2026 (actual)
Oct 21, 2026
Enrollment
30 (estimated)→15 (actual)
Oct 21, 2026
Eligibility
Maximum age 79 Years→85 Years; 1 inclusion criterion edited, 2 added, 3 removed; 2 exclusion criteria edited, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedAt least 22 years of age and less than 80up to 85 years of age
  • RemovedAt least one symptomatic atrial fibrillation episodes per month over the last three months
  • RemovedAF burden of at least 5%, as measured within the past 3 months, with no change in AF treatment since measurement
  • AddedAt least two symptomatic or asymptomatic atrial fibrillation episodes over the last month, or at least one symptomatic or asymptomatic atrial fibrillation episode in the last two weeks
  • AddedOn anticoagulants if indicated by treatment guidelines
  • RemovedAble and willing to use their smartphone to download the application associated with the Cardiac Measurement Device
Exclusion criteria
  • EditedPrior cardiacCardiac ablation within the last 6 months, or cardiac ablation planned within 68 weeks of Visit 1
  • ChangedBefore Left atrial anteroposterior diameter greater than 5.5 cm by transthoracic echocardiographyNow Abnormal left atrial enlargement, as measured by left atrial anteroposterior diameter greater than 5.5 cm or left atrial volume index greater than 48 mL/m2
  • RemovedNot currently on anticoagulants
Oct 21, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedPercentage of time spent in AF during the 4-week treatment period compared to the 2-week run-in period (prior to treatment) for AF episodes >= 30 seconds durationTime frame: 6 weeks → 8 weeks
Oct 21, 2026
Secondary outcomes
11 time frame changed
What changed in the outcomes
  • Time frameTime to first recurrence of any AF (>= 30 seconds duration) during treatment period compared to run-in period6 weeks → 8 weeks
  • Time frameTime to first recurrence of symptomatic AF during treatment period compared to run-in period6 weeks → 8 weeks
  • Time frameAverage AF episode duration during the treatment period compared to the run-in period (for episodes >= 30seconds duration)6 weeks → 8 weeks
  • Time frameNumber of AF episodes lasting >= 5.5 hours6 weeks → 8 weeks
  • Time frameAverage duration of ongoing AF episodes (>= 30 seconds duration) following the start of therapy sessions6 weeks → 8 weeks
  • Time frameAtrial Fibrillation Effect on Quality of Life (AFEQL) score at the end of the treatment period compared to end of the run-in period6 weeks → 8 weeks
  • Time frameCompliance to per-protocol therapy measured by the percentage of full and partial therapy sessions delivered relative to total sessions required per-protocol6 weeks → 8 weeks
  • Time frameCompliance of daily therapy measured by the percentage of treatment days subjects performed full or partial therapy sessions6 weeks → 8 weeks
  • Time frameother outcomeNumber of AF-related emergency visits6 weeks → 8 weeks
  • Time frameother outcomeNumber of AF-related in-patient hospitalizations6 weeks → 8 weeks
  • Time frameother outcomeNumber of cardioversion procedures6 weeks → 8 weeks
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Status unknown→Terminated
    Why stopped The Sponsor and Principal Investigator have mutually agreed to initiate study closure due to prolonged recruitment challenges that have prevented the trial from meeting its enrollment milestones within the projected study timeline.
    Primary completion Dec 2023→Sep 24, 2025 (now actual)
    Study completion Dec 2023→Sep 15, 2026 (now actual)
    Enrollment 30 (estimated)→15 (actual)
    Eligibility Maximum age 79 Years→85 Years; 1 inclusion criterion edited, 2 added, 3 removed; 2 exclusion criteria edited, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedAt least 22 years of age and less than 80up to 85 years of age
    • RemovedAt least one symptomatic atrial fibrillation episodes per month over the last three months
    • RemovedAF burden of at least 5%, as measured within the past 3 months, with no change in AF treatment since measurement
    • AddedAt least two symptomatic or asymptomatic atrial fibrillation episodes over the last month, or at least one symptomatic or asymptomatic atrial fibrillation episode in the last two weeks
    • AddedOn anticoagulants if indicated by treatment guidelines
    • RemovedAble and willing to use their smartphone to download the application associated with the Cardiac Measurement Device
    Exclusion criteria
    • EditedPrior cardiacCardiac ablation within the last 6 months, or cardiac ablation planned within 68 weeks of Visit 1
    • ChangedBefore Left atrial anteroposterior diameter greater than 5.5 cm by transthoracic echocardiographyNow Abnormal left atrial enlargement, as measured by left atrial anteroposterior diameter greater than 5.5 cm or left atrial volume index greater than 48 mL/m2
    • RemovedNot currently on anticoagulants
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedPercentage of time spent in AF during the 4-week treatment period compared to the 2-week run-in period (prior to treatment) for AF episodes >= 30 seconds durationTime frame: 6 weeks → 8 weeks
    Secondary outcomes 11 time frame changed
    What changed in the outcomes
    • Time frameTime to first recurrence of any AF (>= 30 seconds duration) during treatment period compared to run-in period6 weeks → 8 weeks
    • Time frameTime to first recurrence of symptomatic AF during treatment period compared to run-in period6 weeks → 8 weeks
    • Time frameAverage AF episode duration during the treatment period compared to the run-in period (for episodes >= 30seconds duration)6 weeks → 8 weeks
    • Time frameNumber of AF episodes lasting >= 5.5 hours6 weeks → 8 weeks
    • Time frameAverage duration of ongoing AF episodes (>= 30 seconds duration) following the start of therapy sessions6 weeks → 8 weeks
    • Time frameAtrial Fibrillation Effect on Quality of Life (AFEQL) score at the end of the treatment period compared to end of the run-in period6 weeks → 8 weeks
    • Time frameCompliance to per-protocol therapy measured by the percentage of full and partial therapy sessions delivered relative to total sessions required per-protocol6 weeks → 8 weeks
    • Time frameCompliance of daily therapy measured by the percentage of treatment days subjects performed full or partial therapy sessions6 weeks → 8 weeks
    • Time frameother outcomeNumber of AF-related emergency visits6 weeks → 8 weeks
    • Time frameother outcomeNumber of AF-related in-patient hospitalizations6 weeks → 8 weeks
    • Time frameother outcomeNumber of cardioversion procedures6 weeks → 8 weeks
    + 5 other changes: index terms, verification date, description, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05653583
Lead sponsor
Cala Health, Inc.
Responsible party
Sponsor
First posted
Dec 16, 2022
Start date
Mar 8, 2023
Primary completion
Sep 24, 2025
Completion
Sep 15, 2026
Last update
Oct 21, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion